Table 1. Patient characteristics.
N | Percentage (%) | |
---|---|---|
Clinical stage at dx of muscle invasive disease | ||
T1 | 1 | 1 |
T2–T3a | 9 | 11 |
T3b | 3 | 4 |
T4 | 5 | 6 |
Any T, N+ | 8 | 10 |
Any T, any M, M+ | 27 | 33 |
Unknown | 30 | 36 |
Regimen | ||
GC | 32 | 39 |
MVAC | 45 | 54 |
Unknown | 6 | 7 |
ECOG-PS | ||
0 | 46 | 55 |
1 | 32 | 39 |
Unknown | 5 | 6 |
Visceral disease | ||
No | 44 | 53 |
Yes | 33 | 40 |
Unknown | 6 | 7 |
Response | ||
CR | 8 | 10 |
PR | 37 | 45 |
SD | 11 | 13 |
PD | 8 | 10 |
Unknown | 19 | 23 |
PFS | ||
<4 months | 8 | 10 |
>9–12 months | 29 | 36 |
Abbreviations: CR=complete response; dx=diagnosis; ECOG-PS=Eastern Cooperative Oncology Group-performance status; GC=gemcitabine and cisplatin; MVAC=methotrexate, vinblastine, doxorubicin and cisplatin; PFS=progression free survival; PR=partial response; SD=stable disease.